Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05438641 · ClinicalTrials.gov registry record
Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 30
- Enrollment target
NCT05438641: Completed study, sponsored by Stanford University.
NCT05438641 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05438641 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when admitted to medical/surgical units. During the last 15 months, the investigators have implemented a benzodiazepine-sparing management approach with very positive clinical outcomes. The BZDP-sparing protocol consists of a combination of alpha-2 agonist and/or anticonvulsant agents; all currently being used for the management of other medical conditions. This project intends to collect and analyze the data of all subjects managed with this approach to better understand its effectiveness and assess for potential adverse effects.
Interventions
- DRUG BZDP-Sparing Protocol
- DRUG BZDP-Based Protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05438641
The ClinicalTrials.gov registry entry for NCT05438641 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BZDP-Sparing Protocol is the first listed.
NCT05438641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05438641 about?
NCT05438641 is a clinical study titled "Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants". Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when admitted to medical/surgical units. During the last 15 months, the inve...
What is the current status of trial NCT05438641?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-08. Estimated completion is 2017-08.
What interventions are being tested in trial NCT05438641?
The interventions under investigation include: BZDP-Sparing Protocol (DRUG), BZDP-Based Protocol (DRUG).
Who is sponsoring clinical trial NCT05438641?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.